Remibrutinib shows promise for Sjögren’s syndrome treatment
The Bruton’s tyrosine kinase inhibitor remibrutinib reduces disease activity in patients with Sjögren’s syndrome, show results from the phase 2 LOUiSSE trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Young age reduces MS disability but does not fully protect against it
Progression of multiple sclerosis in the absence of relapses can occur at any age, although it is less common in children than adults with the condition, suggests research.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Cognitive decline continues during gantenerumab therapy for Alzheimer’s disease
Gantenerumab has failed to significantly slow cognitive impairment in people with early Alzheimer’s disease in the GRADUATE I and II trials of the anti-Aβ immunoglobulin G1 antibody.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Intestinal mucositis flags bloodstream infections in feverish children with leukaemia
Monitoring biomarkers of intestinal mucositis in children undergoing treatment for acute leukaemia who develop fever may identify those at risk for bloodstream infections (BSIs), Danish researchers have found.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Fingerstick blood test cartridge may improve childhood TB diagnosis
A three-gene Mycobacterium tuberculosis host response cartridge using a fingerstick blood sample has shown promising diagnostic accuracy for childhood tuberculosis, researchers report in The Lancet Infectious Diseases.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Diffusing capacity of lung for carbon monoxide predicts SLE disease severity
The diffusing capacity of the lungs for carbon monoxide could be a surrogate marker for overall disease severity in patients with systemic lupus erythematosus, suggest researchers in Rheumatology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Rationale for antiviral therapy in new-onset type 1 diabetes
Antiviral therapy may preserve residual insulin production in children and adolescents newly diagnosed with type 1 diabetes, suggest findings from the DiViD intervention study.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Upfront dabrafenib plus trametinib supported for paediatric low-grade glioma
First-line treatment with dabrafenib plus trametinib is significantly more likely to achieve a response than chemotherapy for children with low-grade glioma carrying a BRAF V600 alteration, indicates a phase 2 trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
DOPA decarboxylase: a ‘highly promising’ biomarker for Parkinsonian disorders
DOPA decarboxylase could be an effective biomarker for dopaminergic dysfunction, detecting early and preclinical Lewy body disease and atypical Parkinsonian disorders, say researchers.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Complete remission best for tapering SLE treatment
To prevent systemic lupus erythematosus flare, tapering of corticosteroid or immunosuppressive therapy is best done when patients are in complete remission and have maintained stable disease for at least 6 months, say researchers.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
